Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 1 Jul 2018

Pozzi Silvia, Thammisetty Sai Sampath, Julien Jean-Pierre

Abstract excerpt

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which presently does not have any efficient therapeutic approach. Pimozide, a Food and Drug Administration (FDA)-approved neuroepileptic drug, has been recently proposed as a promising treatment for ALS patients based on apparent stabilization of right hand muscles after a short-time administration. A new clinical trial started at the end of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Motor Activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Movement Disorders

Share to Muscle Strength

Share to Neuromuscular Junction

Share to Phosphopyruvate Hydratase

Share to Statistics, Nonparametric

Share to Superoxide Dismutase

Source

Open in PubMed Open full text

Identifiers

PMID: 29790082
DOI: 10.1007/s13311-018-0634-3
PMCID: PMC6095790

Genes

SOD1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.PMID 29790082Read ↗

SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatmentsSemantic proximity Read ↗

Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.Semantic proximity Read ↗

Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future PerspectivesSemantic proximity Read ↗

Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosisSemantic proximity Read ↗

Sporadic amyotrophic lateral sclerosis: integral model of pathogenesis and therapy optionsSemantic proximity Read ↗

Research advances in amyotrophic lateral sclerosis, 2009 to 2010.Semantic proximity Read ↗

Developing and testing therapies for Amyotrophic Lateral Sclerosis (ALS)Semantic proximity Read ↗

Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials.Semantic proximity Read ↗

Inhibition of SOD1 trimerization is a novel drug target for ALS diseaseSemantic proximity Read ↗

Treatment of hereditary amyotrophic lateral sclerosis.Semantic proximity Read ↗

Preclinical testing of potential therapeutics for Amyotrophic Lateral SclerosisSemantic proximity Read ↗

From animal models to human disease: a genetic approach for personalized medicine in ALSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.